Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ERAS-4001 in advanced solid tumors with KRAS mutations
NCT07021898Phase 1Recruiting
- Sponsor
- Erasca
- Start
- Aug 2025
- Primary completion
- Aug 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ERAS-4001 in solid tumor (2 arms), sponsored by Erasca. Primary endpoints: Dose Limiting Toxicities at 21 days, Maximum Tolerated Dose at 21 days and 6 more. Started Aug 2025; status: recruiting.
02
Drugs
ERAS-4001
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07021898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07021898.